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Background
• Abuse-deterrent formulations (ADFs) of extended-release (ER) opioids are designed to target the routes of abuse (crushing or dissolving) to reduce 
opioid abuse in the US
• Little is known about characteristics of patients who initiate ADF opioids, which is important to identify appropriate comparators to address 
confounding by indication
Objective
• To describe demographics and clinical characteristics of patients with prescribed ADF and non-ADF ER opioids 
Conclusions
• Both data sources revealed significant differences in the selected characteristics between patients with ADF and non-ADF ER opioids 
• The prevalence of several types of pain, including acute pain, arthritis pain, and chronic pain, were higher among patients with initiating ADF opioids than in patients with non-ADF ER 
opioids
• The implications for research design include identifying appropriate comparator groups when examining ADF opioid use related outcomes
Methods
Results
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Data source
• Data A: A national data source from IBM Marketscan Commercial claims (2009-2018) 
• Data B: A large private insurance provider in North Carolina [USA] (2009-2018)
Study Design: Retrospective cohort study
Identification of patients with ER opioids: Patients (18-64 years-old) who initiated ER opioids (ADF and non-ADF ER opioids) with having ≥ 6 months of 
washout period prior to the ER initiation
Traditional new user: No opioid claims during 6 months prior to ER opioid initiation (i.e., washout period)
Prevalent new user: Allowed immediate-release (IR) opioid claims during the washout period and excluded the patients with no six-months eligibility 
prior to the first immediate-release (IR) opioid claim 
Table 1. Characteristics of patients with ADF and non-ADF ER opioid analgesics
Data A: ER opioid initiators (N=303,014) Data B: ER opioid initiators (N=20,992)
ADF users(N=101,319) Non-ADF ER users (N=201,695) ADF users(N=7,204) Non-ADF ER users (N=13,788)
Age (mean (SD)) 48.9 (12.2) 49.1 (11.7) 48.4 (11.8) 47.8 (11.3)
Male 53,347 (52.7) 96,867 (48.0) 3,993 (55.4) 6,950 (50.4)
Medications
Gabapentin 9,559 (9.4) 24,909 (12.4) 1,115 (15.5) 2,356 (17.1)
Selective serotonin reuptake inhibitors 14,756 (14.6) 31,747 (15.7) 2,150 (29.8) 4,842 (35.1)
Benzodiazepine 20631 (20.4) 51,289 (25.4) 1,284 (17.8) 2,629 (19.1)
IR opioids 59,242 (58.5) 127,707 (63.3) 4,958 (68.8) 10,206 (74.0)
Diagnosis
Cancer 27,601 (27.2) 67,795 (33.6) 1,359 (18.9) 2,924 (21.2)
Acute pain 56,904 (56.2) 83,889 (41.6) 4,087 (56.7) 5,726 (41.5)
Arthritis pain 35,813 (35.4) 40,709 (20.2) 2,622 (36.4) 3,130 (22.7)
Back/neck pain 33,634 (33.2) 82,919 (41.1) 2,848 (39.5) 7,061 (51.2)
Chronic pain 84,820 (83.7) 14,9854 (74.3) 6,447 (89.5) 11,760 (85.3)
Neuropathic pain 16,958 (16.7) 42,433 (21.0) 1,352 (18.8) 3,566 (25.9)
Data analysis: All data analyses were conducted using SAS 9.4
• Heatmap was generated to examine the patterns of opioid prescriptions in ER initiator (N=150 randomly selected from ER opioid initiator)
• Patients characteristics: Demographics, medications (gabapentin, benzodiazepine, antidepressants, and IR opioids), pain-related symptoms (acute 
pain, arthritis pain, back/neck pain, chronic pain, and neuropathic pain), and cancer were measured during the washout period




• Among patient initiating ER opioids, 
33.4% and 34.3% initiated with ADF 
opioids from Data A and Data B, 
respectively
• Data A: 73.3% and 72.8% of ADF and 
non-ADF ER users were  prevalent new 
users, respectively
• Mean age [standard deviation]: 49.0 
[11.9] (Data A) and 48.4 [11.8] (Data B)
• Male (%): 49.6% (Data A) and 55.4% 
(Data B)
(All results presented are N (%) unless otherwise noted)
All results showed significant differences (p-value <0.01) between patients with ADF and non-ADF ER opioids 
Figure 2. Patterns of opioid prescriptions in ER initiators (150 patients were randomly selected from ER initiators)
Figure 1. Flow diagram of study selection 
Data A and B (2009-2018)
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2)    No follow-up 
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Non-ADF ER user
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